Hyperhomocysteinemia and low pyridoxal phosphate: Common and independent reversible risk factors for coronary artery disease

Circulation

Volumn 92, Issue 10, 1995, Pages 2825-2830

  Robinson, Killian ^a   Mayer, Ellen L ^a   Miller, Dave P ^a   Green, Ralph ^a   Van Lente, Frederick ^a   Gupta, Anjan ^a   Kottke Marchant, Kandice ^a   Savon, Susan R ^a   Selhub, Jacob ^b   Nissen, Steven E ^a   Kutner, Michael ^a   Topol, Eric J ^a   Jacobsen, Donald W ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TUFTS UNIVERSITY   (United States)

Author keywords

coronary disease; vitamins

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXAL 5 PHOSPHATE;

ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; VITAMIN DEFICIENCY;

EID: 0028855901     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.92.10.2825     Document Type: Article

References (36)

1. Wilcken DEL, Wilcken B. The pathogenesis of coronary artery disease: a possible role for methionine metabolism. J Clin Invest. 1976;57:1079-1082.
2. Kang S-S, Wong PWK, Cook HY, Norusis M, Messer JV. Protein-bound homocysteine: a possible risk factor for coronary artery disease. J Clin Invest. 1986;77:1482-1486.
3. Boers GHJ, Smals AGH, Trijbels FJM, Fowler B, Bakkeren JAJM, Schoonderwaldt HC, Kleijer WJ, Kloppenborg PWC. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med. 1985;313:709-715.
4. Brattström L, Israelsson B, Norrving B, Bergqvist D, Thörne J, Hultberg B, Hamfelt A. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease: effects of pyridoxine and folic acid treatment. Atherosclerosis. 1990; 81:51-60.
5. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324:1149-55.
6. Genest JJ Jr, McNamara JR, Salem DN, Wilson PWF, Schaefer EJ, Malinow MR. Plasma homocyst(e)ine levels in men with premature coronary artery disease. J Am Coll Cardiol. 1990;16:1114-1119.
7. Malinow MR, Kang SS, Taylor LM, Wong PWK, Coull B, Inahara T, Mukerjee D, Sexton G, Upson B. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation. 1989;79:1180-1188.
8. Taylor LM Jr, DeFrang RD, Harris J Jr, Porter JM. The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease. J Vasc Surg. 1991;13:128-136.
9. Brattström L, Lindgren A, Israelsson B, Malinow MR, Norrving B, Upson B, Hamfelt A. Hyperhomocysteinaemia in stroke: prevalence, cause and relationships to type of stroke and stroke risk factors. EurJ Clin Invest. 1992;22:214-221.
10. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992;268:877-881.
11. Graham IM. Homocysteinaemia and vascular disease. In Vuylsteek K, Hallen M, eds. Commission of the European Community. Ios Press; 1994:332-353.
12. Wu LL, Wu J, Hunt SC, James BC, Vincent GM, Williams RR, Hopkins PN. Plasma homocysteine as a risk factor for early familial coronary artery disease. Clin Chem. 1994;40:552-561.
13. Pancharuniti N, Lewis CA, Sauberlich HE, Perkins LL, Go RCP, Alvarez JO, Macaluso M, RT Acton, Copeland RB, Cousins AL, Gore TB, Cornwell PE, Roseman JM. Plasma homocyst(e)ine, folate, and vitamin B12 concentrations and risk for early-onset coronary artery disease. Am J Clin Nutr. 1994;59:940-948.
14. Mudd SH, Levy HL, Skovby F. Disorders of transsulfuration. In Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease, New York, NY: McGraw-Hill; 1989:693-734.
15. Kang S-S, Wong PWK, Susmano A, Sora J, Norusis M, Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet. 1991;48: 536-545.
16. Stabler SP, Marcell PD, Podell ER, Allen RH, Savage DG, Lindenbaum J. Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas chromatography-mass spectrometry. J Clin Invest. 1988;81: 466-474.
17. Brattström LE, Israelsson B, Lindgärde F, Hultberg B. Higher total plasma homocysteine in vitamin B12 deficiency than in heterozygosity for homocystinuria due to cystathionine β-synthase deficiency. Metabolism. 1988;37:175-178.
18. Smolin LA, Crenshaw TD, Kurtycz D, Benevenga NJ. Homocyst(e)ine accumulation in pigs fed diets deficient in vitamin B-6: relationship to atherosclerosis. J Nutr. 1983;113:2122-2133.
19. Jacobsen DW, Gatautis VJ, Green R, Robinson K, Savon SR, Secic M, Ji J, Otto JM, Taylor LM Jr. Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate levels in healthy subjects. Clin Chem. 1994;40:873-881.
20. Camp VM, Chipponi J, Faraj BA. Radioenzymatic assay for direct measurement of pyridoxal 5′-phosphate. Clin Chem. 1983;29: 642-644.
21. Carson NAJ, Neill DW. Metabolic abnormalities detected in a survey of mentally backward individuals in Northern Ireland. Arch Dis Child. 1962;37:505-513.
22. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA. 1993;270:2693-2698.
23. Nordström M, Kjellström T. Age dependency of cysthatione beta-synthase activity in human fibroblasts in homocyst(e)inemia and atherosclerotic vascular disease. Atherosclerosis. 1992;94:213-221.
24. Rinehart JF, Greenberg LD. Arteriosclerotic lesions in pyridoxine-deficient monkeys. Am J Pathol. 1949;25:481-491.
25. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PWF, Belanger AJ, O'Leary DH, Wolf PA, Schaefer EJ, Rosenbeg IH. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med. 1995;322: 286-291.
26. Subbarao K, Kuchibhotla J, Kakkar VV. Pyridoxal 5′-phosphate: a new physiological inhibitor of blood coagulation and platelet function. Biochem Pharmacol. 1979;28:531-534.
27. Brattstrom L, Stavenow L, Galvard H, Nilsson-Ehle P, Berntorp E, Jerntorp P, Elmstahl S, Pessah-Rasmussen H. Pyridoxine reduces cholesterol and low-density lipoprotein and increases antithrobmin III activity in 80-year-old men with low plasma pyridoxal 5-phosphate. Scand J Clin Lab Invest. 1990;50:873-877.
28. Ubbink JB, Vermaak WJH, van der Merwe A, Becker PJ. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr. 1993;57:47-53.
29. Brattström LE, Israelsson B, Jeppsson J-O, Hultberg BL. Folic acid: an innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest. 1988;48:215-221.
30. Franken DG, Boers GHJ, Blom HJ, Trijbels FJM, Kloppenborg PWC. Treatment of mild hyperhomocysteinemia in vascular disease patients. Arterioscler Thromb. 1994;14:465-470.
31. Ryan M, Robinson K, Clarke R, Refsum H, Ueland P, Graham I. Vitamin B6 and folate reduce homocysteine concentrations in coronary artery disease. Ir J Med Sci. 1993;162:197. Abstract.
32. Saltzman E, Mason JB, Jacques PF, Selhub J, Salem D, Schaefer EJ, Turissini C, Bendich A, Rosenberg IH. B12 vitamin supplementation lowers homocysteine levels in heart disease. Clin Res. 1994; 42:172A. Abstract.
33. Daly L, Robinson K, Tan KS, Graham IM. Hyperhomocysteinaemia: a metabolic risk factor for coronary artery disease determined by both genetic and environmental influences. Q J Med. 1993;86:685-689.
34. Goyette P, Sumner JS, Milos R, Duncan AM, Rosenblatt DS, Matthews RG, Rozen R. Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Nat Genet. 1994;7:195-200. (Erratum appears in Nat Genet. 1994; 7:551.)
35. Goyette P, Frosst P, Rosenblatt DS, Rozen R. Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype/phenotype correlations in severe methylenetetrahydrofolate reductase deficiency. Am J Hum Genet. 1995;56:1052-1059.
36. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, den Heijer M, Kluijtmans LAJ. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111-113.